PR1-Specific Cytotoxic T-Lymphocyte Infusion With Recurrent Chronic Myelogenous Leukemia (CML) After Allogeneic Hematopoietic Transplantation

NCT00866346 · clinicaltrials.gov ↗
PHASE1
Phase
WITHDRAWN
Status
OTHER
Sponsor class

Stopped Study failed to accrue any patients due to regulatory issues with PR1 vaccine and T cell production.

Conditions

Interventions

Sponsor

M.D. Anderson Cancer Center